Lobectomy in patients with differentiated thyroid cancer: experience of a Chilean tertiary center

Simple item page
dc.article.number106217
dc.contributor.authorFuentes I.
dc.contributor.authorSantana R.
dc.contributor.authorEspinoza M.
dc.contributor.authorArteaga E.
dc.contributor.authorUslar T.
dc.contributor.authorBaudrand R.
dc.contributor.authorGonzalez G.
dc.contributor.authorGuarda F.J.
dc.contributor.authorLustig N.
dc.contributor.authorMosso L.
dc.contributor.authorNilo F.
dc.contributor.authorValenzuela F.
dc.contributor.authorDominguez F.
dc.contributor.authorGonzalez H.E.
dc.contributor.authorMontero P.H.
dc.contributor.authorCruz F.
dc.contributor.authorSolar A.
dc.contributor.authorDominguez J.M.
dc.contributor.otherNCD Risk Factor Collaboration (NCD-RisC)
dc.date.accessioned2024-08-15T08:00:20Z
dc.date.available2024-08-15T08:00:20Z
dc.date.issued2024
dc.description.abstract© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.Purpose: Thyroid lobectomy (TL) is an appropriate treatment for up to 4 cm intrathyroidal differentiated thyroid cancer (DTC). There is scarce data regarding TL outside first-world centers. Our aim is to report a cohort of patients with DTC treated with TL in Chile. Methods: We included DTC patients treated with TL, followed for at least 6 months, characterized their clinicopathological features and classified their risk of recurrence and response to treatment. Results: Eighty-two patients followed for a median of 2.3 years (0.5–7.0). Seventy-three (89%) patients had papillary, 8 (9.8%) follicular and 1 (1.2%) high-grade DTC. The risk of recurrence was low in 56 (68.3%) and intermediate in 26 (31.7%). Eight (9.8%) patients required early completion thyroidectomy and radioiodine. At last follow-up, 52 (70.3%) had excellent, 19 (25.7%) had indeterminate, and 1 (1.4%) had structural incomplete response. Conclusion: In a developing country, TL is an adequate option for appropriately selected DTC patients.
dc.description.funderNational Research and Development Agency of Chile, National Doctoral Scholarship
dc.format.extent1 página
dc.fuente.origenScopus
dc.identifier.doi10.1007/s12020-024-03905-1
dc.identifier.eissn1365-2206
dc.identifier.issn15590100 1355008X
dc.identifier.pubmedid15880187
dc.identifier.scopusidSCOPUS_ID:85195965239
dc.identifier.urihttps://doi.org/10.1007/s12020-024-03905-1
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/87462
dc.identifier.wosidWOS:001246494400001
dc.information.autorucFacultad de Medicina; Mosso Gomez, Lorena Montserrat; S/I; 88201
dc.issue.numero20
dc.language.isoen
dc.nota.accesoContenido parcial
dc.pagina.final2901
dc.pagina.inicio2885
dc.relation.ispartof92nd Meeting and Expo of the Endocrine Society (ENDO 2010), JUN 19-22, 2010, San Diego, CA
dc.revistaEndocrine
dc.rightsacceso restringido
dc.subjectAnti thyroglobulin antibodies
dc.subjectLobectomy
dc.subjectPersonalized medicine
dc.subjectQuality of Life
dc.subjectThyroid cancer
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleLobectomy in patients with differentiated thyroid cancer: experience of a Chilean tertiary center
dc.typeartículo
dc.volumen68
sipa.codpersvinculados88201
sipa.indexScopus
sipa.trazabilidadCarga WOS-SCOPUS;15-08-2024
Files
Collections
Artículos de revistas